Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The company shall process the change of name application with BSE Ltd. in due course
Subscribe To Our Newsletter & Stay Updated